Fulcrum Therapeutics (FULC) Change in Receivables (2020 - 2025)
Fulcrum Therapeutics (FULC) posted quarterly Change in Receivables of -$979000.0 for Q2 2025, down 141.96% year-over-year from $2.3 million in Q2 2024, and up 12.35% quarter-over-quarter from -$1.1 million in Q1 2025.
Fulcrum Therapeutics (FULC) Change in Receivables (2020 - 2025) Analysis & Trends
Fulcrum Therapeutics (FULC) has reported Change in Receivables for 6 consecutive years, with -$979000.0 the latest figure, recorded in Q2 2025.
- In Q2 2025, Change in Receivables fell 141.96% year-over-year to -$979000.0; the TTM figure through Mar 2026 stood at -$979000.0 (down 200.0% YoY), while the FY2025 annual figure was -$2.1 million, down 234.45% from the prior year.
- Change in Receivables rose to -$979000.0 in Q2 2025 per FULC's latest filing, from -$1.1 million in the prior quarter.
- Across five years, Change in Receivables topped out at $2.6 million in Q4 2021 and bottomed at -$5.0 million in Q4 2022.
- Historically, Change in Receivables has averaged -$132687.5 across 5 years, with a median of -$103000.0 in 2023.
- On a YoY basis, Change in Receivables climbed as much as 1840.79% in 2024 and fell as far as 3527.91% in 2024.
- Fulcrum Therapeutics' Change in Receivables stood at $2.6 million in 2021, then plunged by 291.37% to -$5.0 million in 2022, then soared by 99.14% to -$43000.0 in 2023, then plunged by 3527.91% to -$1.6 million in 2024, then jumped by 37.24% to -$979000.0 in 2025.
- Business Quant data shows FULC's Change in Receivables at -$979000.0 in Q2 2025, -$1.1 million in Q1 2025, and -$1.6 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 117.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -483,662.49 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 31.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 37.16 Mn |
| 10 | Fulcrum Therapeutics | 285.31 Mn | 285.31 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -979,000.00 |
| Jun 30, 2025 | -979,000.00 |
| Mar 31, 2025 | -1.12 Mn |
| Mar 31, 2025 | -1.12 Mn |
| Dec 31, 2024 | -1.56 Mn |
| Dec 31, 2024 | -1.56 Mn |
| Sep 30, 2024 | 1.32 Mn |
| Sep 30, 2024 | 1.32 Mn |
| Jun 30, 2024 | 2.33 Mn |
| Jun 30, 2024 | 2.33 Mn |
| Mar 31, 2024 | -537,000.00 |
| Mar 31, 2024 | -537,000.00 |
| Dec 31, 2023 | -43,000.00 |
| Dec 31, 2023 | -43,000.00 |
| Sep 30, 2023 | -76,000.00 |
| Sep 30, 2023 | -76,000.00 |
| Jun 30, 2023 | 557,000.00 |
| Jun 30, 2023 | 557,000.00 |
| Mar 31, 2023 | -130,000.00 |
| Mar 31, 2023 | -130,000.00 |